OTX2 and glioblastoma: We previously identified that mebendazole (MBZ), an FDA-approved low molecular weight benzimidazole derivative with a lengthy track record of safe long-term human use, significantly reduced tumor growth and improved survival in the animal models of glioblastoma multiforme (GBM) and medulloblastoma (Sonic Hedgehog (SHH) Group and c-Myc/OTX2 amplified Group 3) and also reduced tumor formation in a Familial Adenomatous Polyposis (FAP) colon cancer model [17,18,19,20].